WallStSmart
GLMD

Galmed Pharmaceuticals Ltd

NASDAQ: GLMD · HEALTHCARE · BIOTECHNOLOGY

$0.58
-4.67% today

Updated 2026-06-05

Market cap
$4.59M
P/E ratio
P/S ratio
61.38x
EPS (TTM)
$-2.39
Dividend yield
52W range
$0 – $2
Volume
3.8M

Galmed Pharmaceuticals Ltd (GLMD) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-65.32%
ROA
-28.60%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2012$-3.15M
2013$0.00$-17.48M
2014$0.00$-9.10M
2015$0.00$-10.62M
2016$467000.00$-16.95M100.00%-3,614.99%-3,630.19%
2017$1.08M$-12.30M100.00%-1,139.54%-1,133.55%
2018$2.04M$-9.86M100.00%-525.76%-483.61%
2019$0.00$-20.46M
2020$0.00$-28.77M
2021$0.00$-32.47M
2022$0.00$-17.87M
2023$0.00$-6.91M
2024$0.00$-7.52M
2025$0.00$-10.31M

Frequently asked questions

How much free cash flow does GLMD generate?

GLMD produced $-6.32M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is GLMD's balance sheet healthy?

GLMD holds $3.98M in cash and equivalents against — in long-term debt, on $15.78M of shareholder equity. That debt is best read against the cash flow the business throws off each year.